Patent application number | Description | Published |
20080254157 | Herbal composition for inflammatory disorders - This invention relates to a novel herbal composition comprising an extract of flowering and fruiting heads of the plant, | 10-16-2008 |
20090269427 | HERBAL COMPOSITION FOR INFLAMMATORY DISORDERS - This invention relates to a novel herbal composition comprising an extract of flowering and fruiting heads of the plant, | 10-29-2009 |
20100010002 | ANTICANCER USE OF CAFFEIC ACID AND ITS DERIVATIVES - The present invention relates to the use of caffeic acid or a derivative thereof represented by the following general formula (1) | 01-14-2010 |
20100028472 | HERBAL COMPOSITION AND PROCESS FOR ITS PREPARATION - A herbal composition comprising a therapeutically effective amount of the extract of | 02-04-2010 |
20100034746 | ANIMAL MODEL, SYSTEM, AND METHOD FOR SCREENING COMPOUNDS FOR ANTITHROMBOTIC AND/OR THROMBOLYTIC ACTIVITY - The present invention relates to a method for evaluating a test compound for antithrombotic activity, thrombolytic activity, or a combination thereof. This method can include providing or employing a donor test animal and a recipient test animal. The donor and recipient test animals can have been pretreated with test compound. The donor test animal can be configured to provide oxygenated blood to the recipient test animal through a thrombus inducing system. This method also includes initiating transport of blood from the donor test animal to the recipient test animal through the thrombus inducing system. The method can include interrupting respiration of the recipient test animal and determining the length of time that the recipient test animal survives. In this method, a survival time longer than a predetermined threshold time indicates that the test compound has antithrombotic activity, thrombolytic activity, or a combination thereof. | 02-11-2010 |
20100152129 | Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer - Synergistic combinations of gemcitabine with P276-00 or P1446A and their use in the treatment of cancer are disclosed. The invention further describes novel and unique gene signatures comprising gene markers used to monitor the drug response in a subject treated with the said combinations. | 06-17-2010 |
20100168008 | METHOD OF USE OF EPIREGULIN PROTEIN AND NUCLEIC ACID ENCODING THE SAME IN INFLAMMATORY CONDITIONS - The present invention relates to nucleotide and protein sequences of epiregulin and epiregulin like proteins and nucleotides and methods employing them as a drug response marker in inflammatory conditions. The invention also provides epiregulin protein for treatment of inflammatory conditions like psoriasis and rheumatoid arthritis alone or in combination with one or more anti-inflammatory compounds. | 07-01-2010 |
20100305057 | SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER - A novel pharmaceutical combination comprising a cytotoxic antineoplastic agent selected from a the group consisting of paclitaxel, docetaxel, doxorubicin and gemcitabine or a pharmaceutically acceptable salt thereof and at least one cyclin dependent kinase (CDK) inhibitor; wherein the said combination exhibits synergistic effects when used in the treatment of cancer. The invention also relates to a method for the treatment of cancer, using a therapeutically effective amount of the said combination. | 12-02-2010 |
20100305094 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA - Compounds of formula 1: | 12-02-2010 |
20100324026 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA - Compounds of formula 1: | 12-23-2010 |
20110151469 | INTERFERON EPSILON (IFNE1) AS A MARKER FOR TARGETED CANCER THERAPY - The present invention relates to a method employing Interferon Epsilon (IFNE1) as a therapeutic response, prognostic, or pharmacodynamic marker for cancer chemotherapeutic treatment involving the use of cyclin dependent kinase (CDK) inhibitors. The inventors have identified IFNE1 as a biomarker transcript that is upregulated when cancer cells are treated with CDK inhibitors. In an embodiment, the method of the invention includes measuring a level of IFNE1 mRNA or IFNE1 protein in a subject's tumor, blood or other tissue. An increase in the level of IFNE1 compared to control level can indicate that the CDK inhibitor has produced a therapeutic response or can determine whether a tumor is sensitive to a CDK inhibitor. | 06-23-2011 |
20110312528 | Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer - Synergistic combinations of gemcitabine with P276-00 or P1446A and their use in the treatment of cancer are disclosed. The invention further describes novel and unique gene signatures comprising gene markers used to monitor the drug response in a subject treated with the said combinations. | 12-22-2011 |
20120046334 | PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER - The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of formula I or a pharmaceutically acceptable salt or a solvate thereof. The present invention also relates to a method for the treatment of cancer, which method comprises administering to a patient in need of such a treatment, a therapeutically effective amount of the combination. The present invention also relates to the use of a CDK inhibitor selected from the compounds of formula I as a radiosensitizer that enhances the efficacy of radiotherapy for the treatment of cancer, particularly head and neck cancer. | 02-23-2012 |
20120108627 | IMIDAZO [4,5-C]QUINOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS AND/OR INFLAMMATION - The present invention provides the compounds of formula (I): | 05-03-2012 |
20140087012 | PROCESS FOR PREPARATION OF A HERBAL EXTRACT - A process for preparing an extract of | 03-27-2014 |